Sparta Systems Launches TrackWise Mobile Product Suite
Sparta Systems announced that is offering mobile versions of selected TrackWise product suites.
Sparta Systems announced that is offering mobile versions of selected TrackWise product suites. Those products are TrackWise Mobile, TrackWise Mobile Analytics and TrackWise Audit Execution Package. The mobile offerings are designed to improve the operational efficiency and effectiveness of its customers’ increasingly mobile workforce.
As a mobile offering for Apple iOS devices, and Android devices later this year, the company intends them to offer the following expected features:
- Decreased cycle times for approvals and routing by enabling mobile and time-constrained resources to perform critical approvals and reviews;
- More rapid entry of quality events and customer complaints from virtually any location at time of occurrence-- accelerating the investigation and remediation process, and improving compliance;
- Easy to use, intuitive applications; and,
- Fast adoption and roll-out in organizations with geographically dispersed and on-the-road staff
You can read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Reblozyl Misses Primary Endpoint in Phase III Myelofibrosis Trial but Shows Clinical Promise
July 21st 2025The Phase III INDEPENDENCE trial (NCT04717414) failed to meet its primary endpoint of achieving transfusion independence in patients with myelofibrosis-associated anemia treated with Reblozyl (luspatercept-aamt).
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
